NZ750789B2 - Imidazopyrazine syk inhibitors for the treatment of cancers and other hyperproliferative disorders - Google Patents
Imidazopyrazine syk inhibitors for the treatment of cancers and other hyperproliferative disorders Download PDFInfo
- Publication number
- NZ750789B2 NZ750789B2 NZ750789A NZ75078917A NZ750789B2 NZ 750789 B2 NZ750789 B2 NZ 750789B2 NZ 750789 A NZ750789 A NZ 750789A NZ 75078917 A NZ75078917 A NZ 75078917A NZ 750789 B2 NZ750789 B2 NZ 750789B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- wilksar
- annotation
- compound
- subject
- day
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title description 28
- 201000011510 cancer Diseases 0.000 title description 8
- 239000003112 inhibitor Substances 0.000 title description 8
- 230000002401 inhibitory effect Effects 0.000 title description 8
- ZKAMEFMDQNTDFK-UHFFFAOYSA-N 1H-imidazo[4,5-b]pyrazine Chemical compound C1=CN=C2NC=NC2=N1 ZKAMEFMDQNTDFK-UHFFFAOYSA-N 0.000 title description 2
- 230000003463 hyperproliferative Effects 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 68
- 206010002967 Aplastic anaemia Diseases 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims description 25
- 239000011780 sodium chloride Substances 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 description 23
- 208000004235 Neutropenia Diseases 0.000 description 20
- XSMSNFMDVXXHGJ-UHFFFAOYSA-N 6-(1H-indazol-6-yl)-N-(4-morpholin-4-ylphenyl)imidazo[1,2-a]pyrazin-8-amine Chemical compound C1COCCN1C(C=C1)=CC=C1NC1=NC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 XSMSNFMDVXXHGJ-UHFFFAOYSA-N 0.000 description 19
- 229950004136 Entospletinib Drugs 0.000 description 19
- 206010000880 Acute myeloid leukaemia Diseases 0.000 description 15
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 description 15
- 102000008037 Myeloid-Lymphoid Leukemia Protein Human genes 0.000 description 15
- 108010075393 Myeloid-Lymphoid Leukemia Protein Proteins 0.000 description 15
- 230000002354 daily Effects 0.000 description 15
- -1 AZ-1208 Chemical compound 0.000 description 13
- 102100017894 HOXA9 Human genes 0.000 description 13
- 102000000551 Syk Kinase Human genes 0.000 description 13
- 108010016672 Syk Kinase Proteins 0.000 description 13
- 108010027263 homeobox protein HOXA9 Proteins 0.000 description 13
- 208000007502 Anemia Diseases 0.000 description 12
- 201000005510 acute lymphocytic leukemia Diseases 0.000 description 12
- 238000002512 chemotherapy Methods 0.000 description 12
- 210000001772 Blood Platelets Anatomy 0.000 description 11
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 11
- 206010043554 Thrombocytopenia Diseases 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 230000001939 inductive effect Effects 0.000 description 10
- 201000003793 myelodysplastic syndrome Diseases 0.000 description 10
- 201000002364 leukopenia Diseases 0.000 description 9
- 231100001022 leukopenia Toxicity 0.000 description 9
- 238000009097 single-agent therapy Methods 0.000 description 9
- 230000002062 proliferating Effects 0.000 description 8
- 210000000349 Chromosomes Anatomy 0.000 description 7
- 206010024324 Leukaemias Diseases 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 210000003958 Hematopoietic Stem Cells Anatomy 0.000 description 6
- 210000000440 Neutrophils Anatomy 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 230000003482 proton pump inhibitor Effects 0.000 description 6
- 239000000612 proton pump inhibitor Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 210000001185 Bone Marrow Anatomy 0.000 description 5
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 5
- 229940079593 drugs Drugs 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 4
- 208000001490 Dengue Diseases 0.000 description 4
- 206010012310 Dengue fever Diseases 0.000 description 4
- 239000002609 media Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 3
- 206010060945 Bacterial infection Diseases 0.000 description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
- 229960000640 Dactinomycin Drugs 0.000 description 3
- 108010092160 Dactinomycin Proteins 0.000 description 3
- 229960000975 Daunorubicin Drugs 0.000 description 3
- XAUDJQYHKZQPEU-KVQBGUIXSA-N Decitabine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 3
- 229960004679 Doxorubicin Drugs 0.000 description 3
- 229940090044 Injection Drugs 0.000 description 3
- 241000229754 Iva xanthiifolia Species 0.000 description 3
- 241000634212 Penia Species 0.000 description 3
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
- 229920001186 RNA-Seq Polymers 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 3
- 230000000172 allergic Effects 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000001684 chronic Effects 0.000 description 3
- 230000004186 co-expression Effects 0.000 description 3
- 229960003603 decitabine Drugs 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 201000009910 diseases by infectious agent Diseases 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037240 fusion proteins Human genes 0.000 description 3
- 200000000018 inflammatory disease Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000004083 survival Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 230000003612 virological Effects 0.000 description 3
- LXFOLMYKSYSZQS-XKHGBIBOSA-N (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-[[[3-[2-(6-tert-butyl-1H-benzimidazol-2-yl)ethyl]cyclobutyl]-propan-2-ylamino]methyl]oxolane-3,4-diol Chemical compound CC(C)(C)C1=CC=C2NC(CCC3CC(C3)N(C[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)C(C)C)=NC2=C1 LXFOLMYKSYSZQS-XKHGBIBOSA-N 0.000 description 2
- PKWRMUKBEYJEIX-DXXQBUJASA-N (2S)-N-[(2S)-1-[(2R,4S)-2-[[6-fluoro-2-[6-fluoro-3-[[(2R,4S)-4-hydroxy-1-[(2S)-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]pyrrolidin-2-yl]methyl]-1H-indol-2-yl]-1H-indol-3-yl]methyl]-4-hydroxypyrrolidin-1-yl]-1-oxobutan-2-yl]-2-(methylamino)propanam Chemical compound CN[C@@H](C)C(=O)N[C@@H](CC)C(=O)N1C[C@@H](O)C[C@H]1CC1=C(C2=C(C3=CC=C(F)C=C3N2)C[C@H]2N(C[C@@H](O)C2)C(=O)[C@H](CC)NC(=O)[C@H](C)NC)NC2=CC(F)=CC=C12 PKWRMUKBEYJEIX-DXXQBUJASA-N 0.000 description 2
- CFCUWKMKBJTWLW-BGLFSJPPSA-N (2S,3S)-2-[(2S,4R,5R,6R)-4-[(2S,4R,5R,6R)-4-[(2S,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-3-[(1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-6-[(2S,4R,5S,6R)-4-[(2S,4R,5S,6R)-4,5-dih Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BGLFSJPPSA-N 0.000 description 2
- KXMZDGSRSGHMMK-VWLOTQADSA-N 1-(6,7-dihydro-5H-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-N-[(7S)-7-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound N1([C@H]2CCC3=CC=C(C=C3CC2)NC=2N=C(N(N=2)C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)N)CCCC1 KXMZDGSRSGHMMK-VWLOTQADSA-N 0.000 description 2
- PVCULFYROUOVGJ-UHFFFAOYSA-N 1-[2-chloroethyl(methylsulfonyl)amino]-3-methyl-1-methylsulfonylurea Chemical compound CNC(=O)N(S(C)(=O)=O)N(S(C)(=O)=O)CCCl PVCULFYROUOVGJ-UHFFFAOYSA-N 0.000 description 2
- GCWIQUVXWZWCLE-INIZCTEOSA-N 2-[(4S)-6-(4-chlorophenyl)-1-methyl-4H-[1,2]oxazolo[5,4-d][2]benzazepin-4-yl]acetamide Chemical compound N([C@@H](CC(N)=O)C=1ON=C(C=1C1=CC=CC=C11)C)=C1C1=CC=C(Cl)C=C1 GCWIQUVXWZWCLE-INIZCTEOSA-N 0.000 description 2
- JLRIJKVMMZEKDF-UHFFFAOYSA-N 3-N-(1H-indol-5-yl)-5-pyridin-4-ylpyrazine-2,3-diamine Chemical compound N1=C(NC=2C=C3C=CNC3=CC=2)C(N)=NC=C1C1=CC=NC=C1 JLRIJKVMMZEKDF-UHFFFAOYSA-N 0.000 description 2
- MJSHVHLADKXCML-UHFFFAOYSA-N 4-[2-(butylamino)-5-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexan-1-ol Chemical compound C12=NC(NCCCC)=NC=C2C(C=2C=CC(CN3CCN(C)CC3)=CC=2)=CN1C1CCC(O)CC1 MJSHVHLADKXCML-UHFFFAOYSA-N 0.000 description 2
- ZYRLHJIMTROTBO-UHFFFAOYSA-N 6,8-bis(benzylsulfanyl)octanoic acid Chemical compound C=1C=CC=CC=1CSC(CCCCC(=O)O)CCSCC1=CC=CC=C1 ZYRLHJIMTROTBO-UHFFFAOYSA-N 0.000 description 2
- BIIVYFLTOXDAOV-YVEFUNNKSA-N Alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 2
- 229920002395 Aptamer Polymers 0.000 description 2
- 206010003816 Autoimmune disease Diseases 0.000 description 2
- 210000003719 B-Lymphocytes Anatomy 0.000 description 2
- 101700058252 BP01 Proteins 0.000 description 2
- 229950004237 Birinapant Drugs 0.000 description 2
- 102100019451 CD80 Human genes 0.000 description 2
- 101700080477 CD80 Proteins 0.000 description 2
- 206010008805 Chromosomal abnormality Diseases 0.000 description 2
- WDDPHFBMKLOVOX-AYQXTPAHSA-N Clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 2
- 229950009240 Crenolanib Drugs 0.000 description 2
- DYNHJHQFHQTFTP-UHFFFAOYSA-N Crenolanib Chemical compound C=1C=C2N(C=3N=C4C(N5CCC(N)CC5)=CC=CC4=CC=3)C=NC2=CC=1OCC1(C)COC1 DYNHJHQFHQTFTP-UHFFFAOYSA-N 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 2
- 102000031025 DNA-Binding Proteins Human genes 0.000 description 2
- 108091000102 DNA-Binding Proteins Proteins 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 229950003247 Elesclomol Drugs 0.000 description 2
- 102100004573 FLT3 Human genes 0.000 description 2
- 101710009074 FLT3 Proteins 0.000 description 2
- 241000710831 Flavivirus Species 0.000 description 2
- 229950005309 Fostamatinib Drugs 0.000 description 2
- GKDRMWXFWHEQQT-UHFFFAOYSA-N Fostamatinib Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C(NC=3N=C4N(COP(O)(O)=O)C(=O)C(C)(C)OC4=CC=3)C(F)=CN=2)=C1 GKDRMWXFWHEQQT-UHFFFAOYSA-N 0.000 description 2
- 102100010081 HOXA10 Human genes 0.000 description 2
- 101710024120 HOXA10 Proteins 0.000 description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 2
- 206010052210 Infantile genetic agranulocytosis Diseases 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 102000003855 L-lactate dehydrogenases Human genes 0.000 description 2
- 108091000084 L-lactate dehydrogenases Proteins 0.000 description 2
- 229950000340 Laromustine Drugs 0.000 description 2
- 229950011263 Lirilumab Drugs 0.000 description 2
- 208000003747 Lymphoid Leukemia Diseases 0.000 description 2
- 102100019218 MEN1 Human genes 0.000 description 2
- 101700045140 MEN1 Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010027191 Meningioma Diseases 0.000 description 2
- 229920000348 MiR-155 Polymers 0.000 description 2
- 229960004857 Mitomycin Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 229960001156 Mitoxantrone Drugs 0.000 description 2
- 108010061015 Myeloid Ecotropic Viral Integration Site 1 Protein Proteins 0.000 description 2
- 102000011858 Myeloid Ecotropic Viral Integration Site 1 Protein Human genes 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- HYFHYPWGAURHIV-UHFFFAOYSA-N Omacetaxine mepesuccinate Chemical compound C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 description 2
- 229960001592 Paclitaxel Drugs 0.000 description 2
- 229950011410 Pacritinib Drugs 0.000 description 2
- HWXVIOGONBBTBY-ONEGZZNKSA-N Pacritinib Chemical compound C=1C=C(C=2)NC(N=3)=NC=CC=3C(C=3)=CC=CC=3COC\C=C\COCC=2C=1OCCN1CCCC1 HWXVIOGONBBTBY-ONEGZZNKSA-N 0.000 description 2
- 208000006551 Parasitic Disease Diseases 0.000 description 2
- YIQPUIGJQJDJOS-UHFFFAOYSA-N Plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 description 2
- 229960002169 Plerixafor Drugs 0.000 description 2
- 229960003171 Plicamycin Drugs 0.000 description 2
- 102000001253 Protein Kinases Human genes 0.000 description 2
- 208000002098 Purpura, Thrombocytopenic, Idiopathic Diseases 0.000 description 2
- SXTZYIWTRUTYCY-UHFFFAOYSA-N Rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2N=C3[CH]C=CC=C3N=2)=C1C SXTZYIWTRUTYCY-UHFFFAOYSA-N 0.000 description 2
- OWBFCJROIKNMGD-BQYQJAHWSA-N Rigosertib Chemical compound COC1=CC(OC)=CC(OC)=C1\C=C\S(=O)(=O)CC1=CC=C(OC)C(NCC(O)=O)=C1 OWBFCJROIKNMGD-BQYQJAHWSA-N 0.000 description 2
- 229950006764 Rigosertib Drugs 0.000 description 2
- 210000000952 Spleen Anatomy 0.000 description 2
- 206010041635 Spleen disease Diseases 0.000 description 2
- 210000002784 Stomach Anatomy 0.000 description 2
- URLYINUFLXOMHP-HTVVRFAVSA-N TCN-P Chemical compound C=12C3=NC=NC=1N(C)N=C(N)C2=CN3[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O URLYINUFLXOMHP-HTVVRFAVSA-N 0.000 description 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 2
- 229940061353 Temodar Drugs 0.000 description 2
- 229940035295 Ting Drugs 0.000 description 2
- 229950005801 Tosedostat Drugs 0.000 description 2
- 229950003873 Triciribine Drugs 0.000 description 2
- 229940029983 VITAMINS Drugs 0.000 description 2
- 241000863480 Vinca Species 0.000 description 2
- BPQMGSKTAYIVFO-UHFFFAOYSA-N Vismodegib Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1C(=O)NC1=CC=C(Cl)C(C=2N=CC=CC=2)=C1 BPQMGSKTAYIVFO-UHFFFAOYSA-N 0.000 description 2
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 2
- GUWXKKAWLCENJA-WGWHJZDNSA-N [(2R,3S,5R)-5-(2-amino-6-oxo-3H-purin-9-yl)-3-hydroxyoxolan-2-yl]methyl [(2R,3S,5R)-5-(4-amino-2-oxo-1,3,5-triazin-1-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)C1 GUWXKKAWLCENJA-WGWHJZDNSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000240 adjuvant Effects 0.000 description 2
- 230000001058 adult Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229930013930 alkaloids Natural products 0.000 description 2
- 239000003080 antimitotic agent Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 description 2
- 229960003094 belinostat Drugs 0.000 description 2
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 description 2
- 230000003115 biocidal Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 108010063132 birinapant Proteins 0.000 description 2
- 210000004027 cells Anatomy 0.000 description 2
- 229960000928 clofarabine Drugs 0.000 description 2
- FWFGIHPGRQZWIW-SQNIBIBYSA-N cyclopentyl (2S)-2-[[(2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl]amino]-2-phenylacetate Chemical compound O=C([C@@H](NC(=O)[C@@H]([C@H](O)C(=O)NO)CC(C)C)C=1C=CC=CC=1)OC1CCCC1 FWFGIHPGRQZWIW-SQNIBIBYSA-N 0.000 description 2
- 230000002559 cytogenic Effects 0.000 description 2
- 230000003111 delayed Effects 0.000 description 2
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- BKJIXTWSNXCKJH-UHFFFAOYSA-N elesclomol Chemical compound C=1C=CC=CC=1C(=S)N(C)NC(=O)CC(=O)NN(C)C(=S)C1=CC=CC=C1 BKJIXTWSNXCKJH-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- 201000006353 filariasis Diseases 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 201000004108 hypersplenism Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 201000009673 liver disease Diseases 0.000 description 2
- 201000006439 lymphocytic leukemia Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000001404 mediated Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229940005619 omacetaxine Drugs 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000000546 pharmaceutic aid Substances 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 229920000741 poly[N-(2-aminoethyl)glycine] polymer Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrugs Drugs 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 229960004157 rabeprazole Drugs 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 201000004409 schistosomiasis Diseases 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 201000010874 syndrome Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229930003347 taxol Natural products 0.000 description 2
- 102000003995 transcription factors Human genes 0.000 description 2
- 108090000464 transcription factors Proteins 0.000 description 2
- HOGVTUZUJGHKPL-HTVVRFAVSA-N triciribine Chemical compound C=12C3=NC=NC=1N(C)N=C(N)C2=CN3[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HOGVTUZUJGHKPL-HTVVRFAVSA-N 0.000 description 2
- 210000004881 tumor cells Anatomy 0.000 description 2
- 229960004449 vismodegib Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamins Natural products 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- SUBDBMMJDZJVOS-XMMPIXPASA-N (R)-omeprazole Chemical compound C([S@@](=O)C=1NC2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-XMMPIXPASA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- MJIHNNLFOKEZEW-RUZDIDTESA-N 2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-RUZDIDTESA-N 0.000 description 1
- AUVALWUPUHHNQV-UHFFFAOYSA-M 2-carboxy-6-propylphenolate Chemical class CCCC1=CC=CC(C([O-])=O)=C1O AUVALWUPUHHNQV-UHFFFAOYSA-M 0.000 description 1
- CMZHQFXXAAIBKE-UHFFFAOYSA-N 5'-hydroxyomeprazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(CO)C(OC)=C1C CMZHQFXXAAIBKE-UHFFFAOYSA-N 0.000 description 1
- ZBFDAUIVDSSISP-UHFFFAOYSA-N 5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-imidazo[4,5-b]pyridine Chemical compound N=1C2=NC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C ZBFDAUIVDSSISP-UHFFFAOYSA-N 0.000 description 1
- GYQYAJJFPNQOOW-UHFFFAOYSA-N 6-ethyl-3-[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide Chemical compound N1=C(NC2CCOCC2)C(CC)=NC(C(N)=O)=C1NC(C=C1OC)=CC=C1N(CC1)CCC1N1CCN(C)CC1 GYQYAJJFPNQOOW-UHFFFAOYSA-N 0.000 description 1
- 102100004996 ATP12A Human genes 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 241000224422 Acanthamoeba Species 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 241000580482 Acidobacteria Species 0.000 description 1
- 241001156739 Actinobacteria <phylum> Species 0.000 description 1
- 229940009456 Adriamycin Drugs 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000004881 Amebiasis Diseases 0.000 description 1
- 206010001980 Amoebiasis Diseases 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N Amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960001220 Amsacrine Drugs 0.000 description 1
- 208000009094 Anemia, Hemolytic, Autoimmune Diseases 0.000 description 1
- 241001142141 Aquificae <phylum> Species 0.000 description 1
- 241001167018 Aroa Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 102100017711 BLNK Human genes 0.000 description 1
- 101700001790 BLNK Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000605059 Bacteroidetes Species 0.000 description 1
- 208000007456 Balantidiasis Diseases 0.000 description 1
- 210000003651 Basophils Anatomy 0.000 description 1
- 102000004441 Bcr-abl fusion proteins Human genes 0.000 description 1
- 108010056708 Bcr-abl fusion proteins Proteins 0.000 description 1
- OYVAGSVQBOHSSS-WXFSZRTFSA-O Bleomycin Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-WXFSZRTFSA-O 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 210000000481 Breast Anatomy 0.000 description 1
- JHLNERQLKQQLRZ-UHFFFAOYSA-N Calcium silicate Chemical compound [Ca+2].[Ca+2].[O-][Si]([O-])([O-])[O-] JHLNERQLKQQLRZ-UHFFFAOYSA-N 0.000 description 1
- 241000949049 Caldiserica Species 0.000 description 1
- 229960004562 Carboplatin Drugs 0.000 description 1
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 description 1
- 208000004918 Cartilage-hair hypoplasia Diseases 0.000 description 1
- 229920002301 Cellulose acetate Polymers 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N Cetyl alcohol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 201000003884 Chagas disease Diseases 0.000 description 1
- 241001502567 Chikungunya virus Species 0.000 description 1
- 241001185363 Chlamydiae Species 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 Chlorambucil Drugs 0.000 description 1
- 241000191368 Chlorobi Species 0.000 description 1
- 241001142109 Chloroflexi Species 0.000 description 1
- 206010061764 Chromosomal deletion Diseases 0.000 description 1
- 241001143290 Chrysiogenetes <phylum> Species 0.000 description 1
- 206010009344 Clonorchiasis Diseases 0.000 description 1
- 241000933851 Cochliomyia Species 0.000 description 1
- 206010010445 Congenital disorder Diseases 0.000 description 1
- 206010062759 Congenital dyskeratosis Diseases 0.000 description 1
- 208000008953 Cryptosporidiosis Diseases 0.000 description 1
- 206010011502 Cryptosporidiosis infection Diseases 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- 208000000280 Cyclic neutropenia Diseases 0.000 description 1
- 229960004397 Cyclophosphamide Drugs 0.000 description 1
- 229960000684 Cytarabine Drugs 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940059359 Dacogen Drugs 0.000 description 1
- 241001143296 Deferribacteres <phylum> Species 0.000 description 1
- 241000192095 Deinococcus-Thermus Species 0.000 description 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N Dexlansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000970811 Dictyoglomi Species 0.000 description 1
- 206010013029 Diphyllobothriasis Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 201000010374 Down syndrome Diseases 0.000 description 1
- 208000008576 Dracunculiasis Diseases 0.000 description 1
- 210000001198 Duodenum Anatomy 0.000 description 1
- 208000009356 Dyskeratosis Congenita Diseases 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- 229960001904 EPIRUBICIN Drugs 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 208000006036 Elephantiasis Diseases 0.000 description 1
- 241001260322 Elusimicrobia <phylum> Species 0.000 description 1
- 206010014599 Encephalitis Diseases 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 206010014881 Enterobiasis Diseases 0.000 description 1
- 210000003979 Eosinophils Anatomy 0.000 description 1
- 208000000832 Equine Encephalomyelitis Diseases 0.000 description 1
- 241001125671 Eretmochelys imbricata Species 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N Esomeprazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- 208000002047 Essential Thrombocythemia Diseases 0.000 description 1
- 229960005420 Etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 230000036826 Excretion Effects 0.000 description 1
- 208000006275 Fascioliasis Diseases 0.000 description 1
- 206010016235 Fasciolopsiasis Diseases 0.000 description 1
- 208000002633 Febrile Neutropenia Diseases 0.000 description 1
- 241000923108 Fibrobacteres Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010016880 Folate deficiency Diseases 0.000 description 1
- 229960000304 Folic Acid Drugs 0.000 description 1
- 241001453172 Fusobacteria Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229940014259 Gelatin Drugs 0.000 description 1
- 241001265526 Gemmatimonadetes <phylum> Species 0.000 description 1
- 229940065521 Glucocorticoid inhalants for obstructive airway disease Drugs 0.000 description 1
- 102000002794 Glucosephosphate Dehydrogenase Human genes 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 206010018464 Glycogen storage disease type I Diseases 0.000 description 1
- 208000000807 Gnathostomiasis Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000006572 Human Influenza Diseases 0.000 description 1
- 208000007188 Hymenolepiasis Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 101700024037 IDH1 Proteins 0.000 description 1
- 102100004121 IDH1 Human genes 0.000 description 1
- 101700030371 IDH2 Proteins 0.000 description 1
- 102100002772 IDH2 Human genes 0.000 description 1
- 101700066748 IDH3B Proteins 0.000 description 1
- 229960000908 Idarubicin Drugs 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- 206010051645 Idiopathic neutropenia Diseases 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 Ifosfamide Drugs 0.000 description 1
- 206010022000 Influenza Diseases 0.000 description 1
- HAEJPQIATWHALX-KQYNXXCUSA-N Inosine triphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(N=CNC2=O)=C2N=C1 HAEJPQIATWHALX-KQYNXXCUSA-N 0.000 description 1
- 206010023076 Isosporiasis Diseases 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 210000000822 Killer Cells, Natural Anatomy 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 241001387859 Lentisphaerae Species 0.000 description 1
- 235000001008 Leptadenia hastata Nutrition 0.000 description 1
- 244000074209 Leptadenia hastata Species 0.000 description 1
- 208000009874 Lice Infestations Diseases 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 206010024887 Louping ill Diseases 0.000 description 1
- 206010025169 Lyme disease Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101700002093 MEIS1 Proteins 0.000 description 1
- 102100010482 MEIS1 Human genes 0.000 description 1
- 210000002540 Macrophages Anatomy 0.000 description 1
- 241001115401 Marburgvirus Species 0.000 description 1
- 210000000138 Mast Cells Anatomy 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 206010061289 Metastatic neoplasm Diseases 0.000 description 1
- 206010027527 Microangiopathic haemolytic anaemia Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 210000001616 Monocytes Anatomy 0.000 description 1
- 201000005805 Murray Valley encephalitis Diseases 0.000 description 1
- 206010028537 Myelofibrosis Diseases 0.000 description 1
- 210000000066 Myeloid Cells Anatomy 0.000 description 1
- 208000006123 Myiasis Diseases 0.000 description 1
- 241000288894 Myotis Species 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229940086322 Navelbine Drugs 0.000 description 1
- 240000003492 Neolamarckia cadamba Species 0.000 description 1
- 206010058116 Nephrogenic anaemia Diseases 0.000 description 1
- 206010029151 Nephropathy Diseases 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N Nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- 241000192121 Nitrospira <genus> Species 0.000 description 1
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
- 229950006344 Nocodazole Drugs 0.000 description 1
- 206010030310 Omsk haemorrhagic fever Diseases 0.000 description 1
- 241000243985 Onchocerca volvulus Species 0.000 description 1
- 208000002042 Onchocerciasis Diseases 0.000 description 1
- 210000002997 Osteoclasts Anatomy 0.000 description 1
- 206010025310 Other lymphomas Diseases 0.000 description 1
- 102100004939 PDGFRB Human genes 0.000 description 1
- 101700037337 PIGA Proteins 0.000 description 1
- 102100012341 PIGA Human genes 0.000 description 1
- FWZRWHZDXBDTFK-ZHACJKMWSA-N Panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 description 1
- GRHYHJAAOJVRSZ-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2N=C3[CH]C(OC(F)F)=CC=C3N=2)=C1OC GRHYHJAAOJVRSZ-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108091000081 Phosphotransferases Proteins 0.000 description 1
- 229940023488 Pill Drugs 0.000 description 1
- 241001180199 Planctomycetes Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- JHDKZFFAIZKUCU-ZRDIBKRKSA-N Pracinostat Chemical compound ONC(=O)/C=C/C1=CC=C2N(CCN(CC)CC)C(CCCC)=NC2=C1 JHDKZFFAIZKUCU-ZRDIBKRKSA-N 0.000 description 1
- 229950003618 Pracinostat Drugs 0.000 description 1
- 208000003476 Primary Myelofibrosis Diseases 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N Procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 210000002307 Prostate Anatomy 0.000 description 1
- 108060006633 Protein Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108010083204 Proton Pumps Proteins 0.000 description 1
- CVWXJKQAOSCOAB-UHFFFAOYSA-N Quizartinib Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2N=C3N(C4=CC=C(OCCN5CCOCC5)C=C4S3)C=2)=N1 CVWXJKQAOSCOAB-UHFFFAOYSA-N 0.000 description 1
- 229950001626 Quizartinib Drugs 0.000 description 1
- 206010038428 Renal disease Diseases 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- 241000220010 Rhode Species 0.000 description 1
- 206010056378 Russian spring-summer encephalitis Diseases 0.000 description 1
- 208000005687 Scabies Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N Selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
- 229950010746 Selumetinib Drugs 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 235000015076 Shorea robusta Nutrition 0.000 description 1
- 208000007056 Sickle Cell Anemia Diseases 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 206010041509 Spherocytic anaemia Diseases 0.000 description 1
- 241001180364 Spirochaetes Species 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 206010041896 St. Louis encephalitis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010042254 Strongyloidiasis Diseases 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 229940037128 Systemic Glucocorticoids Drugs 0.000 description 1
- 210000001744 T-Lymphocytes Anatomy 0.000 description 1
- 229940063683 Taxotere Drugs 0.000 description 1
- 229950008375 Tenatoprazole Drugs 0.000 description 1
- 241000131694 Tenericutes Species 0.000 description 1
- 229960001278 Teniposide Drugs 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 241001143138 Thermodesulfobacteria <phylum> Species 0.000 description 1
- 241001141092 Thermomicrobia Species 0.000 description 1
- 241001143310 Thermotogae <phylum> Species 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N ThioTEPA Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 208000004006 Tick-Borne Encephalitis Diseases 0.000 description 1
- 231100000765 Toxin Toxicity 0.000 description 1
- 206010044269 Toxocariasis Diseases 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000009920 Trichuriasis Diseases 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 206010053871 Trisomy 8 Diseases 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 210000003932 Urinary Bladder Anatomy 0.000 description 1
- 241001261005 Verrucomicrobia Species 0.000 description 1
- 241000464917 Vieja Species 0.000 description 1
- 229960003048 Vinblastine Drugs 0.000 description 1
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229960004528 Vincristine Drugs 0.000 description 1
- 206010047461 Viral infection Diseases 0.000 description 1
- 208000001756 Virus Disease Diseases 0.000 description 1
- 208000002670 Vitamin B 12 Deficiency Diseases 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003629 Vitamin B6 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 229960000237 Vorinostat Drugs 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N Vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 241000244005 Wuchereria bancrofti Species 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 229950005752 Zosuquidar Drugs 0.000 description 1
- IHOVFYSQUDPMCN-XAKVHENESA-N Zosuquidar Chemical compound C([C@H](COC=1C2=CC=CN=C2C=CC=1)O)N(CC1)CCN1C1C2=CC=CC=C2[C@H]2C(F)(F)[C@H]2C2=CC=CC=C12 IHOVFYSQUDPMCN-XAKVHENESA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000019169 all-trans-retinol Nutrition 0.000 description 1
- 239000011717 all-trans-retinol Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Natural products OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000000844 anti-bacterial Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 201000009361 ascariasis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 201000008680 babesiosis Diseases 0.000 description 1
- 201000010642 baylisascariasis Diseases 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 201000009030 carcinoma Diseases 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 201000008779 central nervous system disease Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 125000003346 cobalamin group Chemical group 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 230000002596 correlated Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 201000001546 cyclic hematopoiesis Diseases 0.000 description 1
- 201000008167 cystoisosporiasis Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960003568 dexlansoprazole Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 201000008286 diarrhea Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000002612 dispersion media Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 201000009084 dysgammaglobulinemia Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 229930013356 epothilones Natural products 0.000 description 1
- 229960004770 esomeprazole Drugs 0.000 description 1
- KWORUUGOSLYAGD-YPPDDXJESA-N esomeprazole magnesium Chemical compound [Mg+2].C([S@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C.C([S@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C KWORUUGOSLYAGD-YPPDDXJESA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002349 favourable Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002538 fungal Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 201000006592 giardiasis Diseases 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 201000000128 gnathomiasis Diseases 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002489 hematologic Effects 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 201000001505 hemoglobinuria Diseases 0.000 description 1
- 230000002949 hemolytic Effects 0.000 description 1
- 201000001066 hemolytic-uremic syndrome Diseases 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 201000006675 intestinal schistosomiasis Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229960003174 lansoprazole Drugs 0.000 description 1
- 200000000011 liver disorder Diseases 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000001115 mace Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000003519 mature B lymphocyte Anatomy 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 201000011475 meningoencephalitis Diseases 0.000 description 1
- 201000001198 metagonimiasis Diseases 0.000 description 1
- 230000001394 metastastic Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000000877 morphologic Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000000422 nocturnal Effects 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 230000002148 osteoclast Effects 0.000 description 1
- 229960005184 panobinostat Drugs 0.000 description 1
- 229960005019 pantoprazole Drugs 0.000 description 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 230000000541 pulsatile Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 208000007484 severe chronic Neutropenia Diseases 0.000 description 1
- 201000006681 severe congenital neutropenia Diseases 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000000576 supplementary Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000003491 tear gas Substances 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 201000003067 thrombocytopenia due to platelet alloimmunization Diseases 0.000 description 1
- 201000007023 thrombotic thrombocytopenic purpura Diseases 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N tin hydride Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108020003112 toxins Proteins 0.000 description 1
- 201000005485 toxoplasmosis Diseases 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 230000002103 transcriptional Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- CILBMBUYJCWATM-IJDPFCGHSA-N vinorelbine L-tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-IJDPFCGHSA-N 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Abstract
The application provides methods of treating or reducing aplastic anemia in a patient in need thereof, comprising the step of administering an effective amount of a compound selected from Compounds 1-6, disclosed herein.
Description
IMIDAZOPYRAZINE SYK INHIBITORS FOR THE TREATMENT OF S
AND OTHER HYPERPROLIFERATIVE DISORDERS
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims the benefit under 35 U.S.C. § 119(e) of United States
Provisional Application Nos. 62/394,573, filed September 14, 2016, 62/416,047, filed
er 1, 2016; and 62/429,209, filed December 2, 2016, which are hereby incorporated
by reference in their entirety.
FIELD
The present disclosure relates to methods of treatment of diseases and disorders
using compounds and compositions that inhibit Spleen ne Kinase (SYK) activity.
BACKGROUND
Protein kinases, the largest family of human s, encompass well over 500
proteins. Spleen Tyrosine Kinase (SYK) is a member of the family of tyrosine kinases, and is
a regulator of early B-cell development as well as mature B-cell activation, signaling, and
survival. SYK has roles in immunoreceptor- and in-mediated signaling in a variety of
cell types, including B-cells, macrophages, monocytes, mast cells, eosinophils, basophils,
neutrophils, tic cells, s, natural killer cells, platelets, and osteoclasts. The
inhibition of Syk ty can be useful for the treatment cancers and inflammatory diseases.
U.S. Patents 8,455,493, 8,440,667, 9,376,441, 111, 9,353,066 and 9,376,418 disclose
SYK inhibitors. Several SYK inhibitors are in advanced stages of clinical trials. Fostamatinib
is a SYK inhibitor currently undergoing phase III clinical trials for chronic immune
thrombocytopenic purpura (chronic ITP). (NCT02076412; Clinicaltrials.gov). Fostamatinib,
however, has adverse side s including ension, penia and transaminitis.
(Nijjar J.S., et al., Rheumatology 2013, 1556-1562).
SUMMARY
Some embodiments provide methods for treating or reducing thrombocytopenia,
leukopenia, anemia, or neutropenia in a patient in need thereof, comprising the step of
administering an effective amount of a compound selected from:
[Annotation] r
None set by wilksar
[Annotation] wilksar
MigrationNone set by wilksar
[Annotation] wilksar
ed set by wilksar
[Annotation] wilksar
None set by wilksar
[Annotation] wilksar
MigrationNone set by wilksar
[Annotation] wilksar
Unmarked set by wilksar
H W? HZN ,Nj/RNJ
N\ IN\
3 3
Compound-l Compound-2
N/ /N
HZN ”YVNJ)
3 3
Compound-3
Compound-5 Compound-6
or a ceutically acceptable salt, ester or derivative thereof. Some embodiments
provide methods of treatment for anemia, thrombocytopenia, leukopenia or penia
wherein said patient is not undergoing chemotherapy.
Some embodiments provide methods for treating a disease or condition
selected from the group ting of an inflammatory disorder, an allergic disorder, an
autoimmune e, and a cancer in a subject in need thereof, the method comprising
administering to the human in need thereof a therapeutically effective amount of a
[Annotation] wilksar
None set by wilksar
[Annotation] wilksar
ionNone set by wilksar
[Annotation] wilksar
Unmarked set by wilksar
ation] wilksar
None set by wilksar
[Annotation] wilksar
MigrationNone set by wilksar
[Annotation] wilksar
Unmarked set by wilksar
compound selected from Compounds 1-6, or a pharmaceutically acceptable salt, ester or
derivative thereof, wherein said subject is additionally undergoing proton pump inhibitor
therapy; and, wherein said compound selected from Compounds 1-6 is administered at a
daily dosage of about 25% to about 75% higher than the daily dosage recommended for a
subject not undergoing proton pump inhibitor therapy.
Some embodiments provide methods for treating a proliferative disease or
disorder in a subject in need thereof, sing the step of administering a
therapeutically effective amount of a compound selected from Compounds 1-6, or a
pharmaceutically acceptable salt thereof, to said subject, wherein said subject has one or
more abnormal core-binding karyotypes ed from )(q22,q22),
inv(16)(p13.1q22) and t(16,16)(p13.1,q22), or wherein said subject has one or more
chromosomal abnormalities selected from the deletion of 5, 5q, 7, 7q, 17p,
inv(3)(q21,q26) and t(3,3)(q21,q26), or n said subject has a 11q23 rearrangement
of MLL gene.
Some embodiments provide methods for treating a proliferative disease or
disorder in a subject in need thereof, comprising the step of administering a
eutically effective amount of a compound selected from Compounds 1-6, or a
pharmaceutically able salt thereof, to said subject, wherein said subject has mixed
e leukaemia gene-partial tandem ations (MLL-PTD). MLL-PTD confer a
worse prognosis with shortened overall and event free survival in childhood and adult
AML. (Basecke J., et al., British Journal ofHematology, 2006, 135(4):).
Some embodiments provide methods for treating a proliferative disease or
er in a subject in need thereof, comprising the step of administering a
therapeutically effective amount of a compound selected from Compounds 1-6, or a
pharmaceutically acceptable salt thereof, to said t, wherein said subject has or
ses a mixed lineage leukemia (MLL) fusion protein, a BCR-ABL fusion protein,
FLT3 internal tandem duplications, NPMl mutation, IDH1 mutation, IDH2 mutation, a
deleted or d p53, high or elevated levels of meningioma 1, and/or high or levels of
lactate dehydrogenase. MLL fusion partners can vary and more than 51 fusion rs
have been identified. MLL/AF9 often results in AML while MLL/AF4 oftent results in
age ALL. (Basecke J. et al, supra). Some ments provide methods for
identifying abnormal MLL fusion protein expression in a patient followed by the
[Annotation] r
None set by wilksar
[Annotation] wilksar
MigrationNone set by wilksar
[Annotation] wilksar
Unmarked set by wilksar
[Annotation] wilksar
None set by wilksar
[Annotation] wilksar
MigrationNone set by wilksar
ation] wilksar
Unmarked set by wilksar
administration of a compound selected from Compounds 1-6, or a pharmaceutically
acceptable salt thereof to a patient in need f.
Homeobox (HOX) proteins are homeo-domain DNA binding transcription
factors that play an important role in regulation of hematopoiesis (Sitwala, Int. J. Clin.
Exp. Pathol. 2008, Mar 30, 1(6):461-74). Myeloid Ecotropic Viral Integration Site 1
(MEISl) is a co-factor of ox A9 ) that recruits additional DNA binding
proteins to HOXA9 binding sites in order to maintain the Mixed Lineage Leukemia
(MLL) stem cell riptional program ns, Curr. Opin. Hematol. 2016, Jul,
23(4):354-61). Overexpression of these two ns in hematopoietic stem cells (HSCs)
results in a rapid and fatal leukemia when transduced HSCs are transplanted in mice
(Thorsteinsdottir, EMBO J. 2001, Feb 1, 20(3):350-61). A subset of acute lymphoid
leukemia (ALL), pro-B-acute lymphocytic leukemia (pro-B ALL), myelodysplastic
syndrome (MDS) and T-ALL patients can be characterized by tumor cells collected from
bone marrow showing high co-eXpression of HOXA9 and MEISl that are associated
with increased SYK protein levels. Some embodiments provide a method for treating
ts with ALL, pro-B ALL, MDS, AML, MDS and T-ALL where HOXA9 and
MEISl are overeXpressed by the administration of a therapeutically ive amount of
a SYK inhibitor selected from Compounds 1-6, or a pharmaceutically acceptable salt,
ester or derivative thereof
Some embodiments provide methods for ng a proliferative disease or
disorder in a subject in need thereof, comprising the step of administering a
therapeutically effective amount of a compound selected from Compounds 1-6, or a
pharmaceutically acceptable salt f, to said t, wherein said subject is
administered one or more anti-cancer agents selected from the group consisting of AMG—
330, anti-miR155, AntiJL-1+, CD117-MTX aptamer, CD47mAb, CD-98mAb, c,
hBF4-mAb, LAIRl-mAb, IL-IRAP-mAb, MG006, miR-150, MRX-6313, MSK-777,
SP-2065, SPM-2, SIRPOLFc, TTT-3002, MLL/Menin inhibitor, AML-IL2/CD80,
EM, AG—221, , AKN-028, ALT 801, Anti-CD44 mAb, 15, AT-
109, AT-406, AT-9283, AZ-1208, BGB-324, BI 836858, EMS-936564, BP01,
Carbozatinib, CB-839, CART-CD123, CART-CD33, CPI-613, CPI-0610, CSL-362,
2291, Dacogen, Dinacilib, DC/AML fusion, Elesclomol, EPZ-5676,
GSK2879552, IGN 523, INNO-305, Iomab-B, KX-2391, LeY, LOR-253, MK-8242,
[Annotation] wilksar
None set by wilksar
[Annotation] wilksar
MigrationNone set by wilksar
[Annotation] wilksar
Unmarked set by wilksar
[Annotation] wilksar
None set by wilksar
[Annotation] wilksar
MigrationNone set by wilksar
[Annotation] wilksar
Unmarked set by wilksar
MGD006, Oxi-4503, PF-449913, Plerixafor, PRI-724, Rebistanib, Rigosertib, RO-
5503781, PF-04449913, SG—2000, SL-401, SGN-CD33a, TCN-P, Tiecycline,
Triciribine, Vismodegib, idar, Actimab-A, AEG 35156, Belinostat, B1811283,
Bismab-A, Birinapant, BL-8040, , CNDO-109, Crenolanib, Deformolus, DFP-
10917, Flavopiridol, GVAX, KB-004, KPT-330, Lestartinib, Lirilumab, LO-02040,
LY209314, MK8776, Omacetaxine, Pacritinib, nostat, PD-616, umab, PR-
104, ostat, PLX-3397, R—115777, Ribovarin, tinib, SGI-110, nib,
Tresosulfan, Temodar, Tosedostat, stat, WT-1, Arsenix trioxide, Clofarabine,
Decitabine, Laromustine, Tipfarnib, Palbocyclib, Quizartinib and Mylotarg.
DESCRIPTION OF THE FIGURES
Neutrophil counts in patients receiving chemotherapy and 200 or 400
mg twice daily dose of entospletinib (ENTO or Compound-1). The figure shows daily
levels for individual patients and neutrophil recovery through induction treatment.
Platelet counts in patients receiving herapy and 200 or 400 mg
doses of entospletinib (ENTO or Compound-1). The figure shows daily levels for
individual patients and platelet recovery h induction treatment.
Platelet recovery during the entospletinib (ENTO or Compound-1)
monotherapy lead-in window.
Scatter Plot of MEIS1 and a HOXA10 Expression in Leukemia
Subtypes. Leukemia subtypes with high co-expression 10 and MEISl are
boxed in red. Healthy bone marrow is boxed in blue. Data source: Microarray
Innovations in Leukemia (MILE) study (GSE13159, PMID: 18573112 and 20406941).
HOXA10 and HOXA9 RNA sion is Highly Correlated in
AML. Data Source: The Cancer Genome Atlas , RNAseq data, release
2016_01_28.
Expression of HOXA9 and MEIS1 RNA in Cancer Types from
TCGA. MEISl and HOXA9 RNA levels were plotted for cancers in the TCGA. Blue
lines in each panel represent the linear regression line. The red box signifies the high
HOXA9 and MEISl population in AML. Data Source: TCGA, RNAseq data, release
2016_01_28.
[Annotation] wilksar
None set by wilksar
[Annotation] wilksar
MigrationNone set by wilksar
[Annotation] wilksar
ed set by wilksar
[Annotation] wilksar
None set by wilksar
[Annotation] wilksar
MigrationNone set by wilksar
[Annotation] r
ed set by wilksar
Expression of HOXA9 and MEISl RNA in Tumor and Normal from
Bladder, Breast Invasive Carcinoma, Prostate and Uterine s from TCGA Data.
Data Source: TCGA, RNAseq data, release 2016_01_28.
DETAILED DESCRIPTION
Some embodiments provide methods for treating or reducing
thrombocytopenia, enia, anemia, or neutropenia in a patient in need thereof,
comprising the step of administering an effective amount of a compound selected from:
0/} “/1
K/NONH K/
3 3
Compound-1 Compound-2
C C
9 9
Mk”\ N&N
H2N /N \N/ H2N /N \N\/)
I I l I N and
Compound-5 Compound-6
[Annotation] wilksar
None set by wilksar
[Annotation] wilksar
MigrationNone set by wilksar
[Annotation] wilksar
Unmarked set by wilksar
ation] wilksar
None set by wilksar
[Annotation] wilksar
MigrationNone set by wilksar
[Annotation] wilksar
Unmarked set by wilksar
or a pharmaceutically able salt, ester or derivative thereof. Some embodiments
provide methods of treatment for anemia, thrombocytopenia, enia or neutropenia
wherein said patient is not undergoing chemotherapy.
Without being bound to a mechanism or theory, the disclosure herein
provides methods to increase neutrophil and platelet levels in patients in need thereof. It
is the expectation that the compounds herein will be useful in the treatment of, for
example, conditions that cause or exacerbate neutropenia, anemia, leukopenia and
thrombocytopenia.
Some embodiments provide methods for treating anemia comprising the step
of stering a therapeutically effective amount of a compound ed from
Compounds 1-6 to a subject in need thereof. In some embodiments, anemia is selected
from the group consisting of hemolytic , microangiopathic hemolytic anemia,
hypersplenism, thropoietic anemia, spherocytosis, sideroblastic ,
autoimmune hemolytic anemia, sickle cell anemia, thalassemia, Glucosephosphate
dehydrogenase —def1cient anemia, ious , aplastic anemia, anemia
caused by liver disease or renal disease, and anemia caused by the deficiency of one or
more vitamins or nutrients. Some embodiments e a method of treatment where
anemia is caused by deficiency of one or more nutrients or vitamins, for example, a
vitamin B12, B2, B6, C, A1, D, E or K, iron, folic acid, zinc, copper, calcium or protein.
Some embodiments provide methods for treating thrombocytopenia
comprising the step of administering a therapeutically effective amount of a compound
selected from Compounds 1-6 to a subject in need thereof In some embodiments,
thrombocytopenia is selected from idiopathic thrombocytopenia, alcohol-induced
thrombocytopenia, drug-induced immune ocytopenia, thrombotic
thrombocytopenic purpura, transfusion-induced thrombocytopenia, primary
thrombocythemia, disseminated ascular coagulation, hypersplenism, hemolytic
uremic syndrome, paroxysmal nocturnal hemoglobinuria and immune thrombocytopenia.
In some embodiments, thrombocytopenia is due to low production of platelets in bone
marrow, while in some embodiments, it is due to increased own of platelets in the
bloodstream, spleen or liver, or due to lution.
Some embodiments provide methods for treating neutropenia comprising the
step of administering a therapeutically ive amount of a compound selected from
[Annotation] wilksar
None set by wilksar
[Annotation] wilksar
MigrationNone set by wilksar
[Annotation] wilksar
Unmarked set by wilksar
[Annotation] wilksar
None set by wilksar
[Annotation] wilksar
MigrationNone set by r
[Annotation] wilksar
ed set by wilksar
Compounds 1-6 to a t in need thereof. In some embodiments, neutropenia is
selected from primary neutropenia, acute neutropenia, severe chronic neutropenia, severe
congenital neutropenia (Kostmann's syndrome), severe infantile genetic agranulocytosis,
benign neutropenia, cyclic neutropenia, chronic idiopathic neutropenia, secondary
neutropenia, syndrome ated penia, and immune-mediated neutropenia.
Some embodiments provide methods for treating neutropenia comprising the
step of administering a therapeutically effective amount of a compound selected from
Compounds 1-6 to a subject in need thereof, wherein neutropenia is caused or ated
with ion, alcoholism, allergic disorders, aplastic anemia, autoimmune disease,
myelodysplasia, myelofibrosis, dysgammaglobulinemia, smal nocturnal
hemoglobinuria, vitamin B12 deficiency, folate deficiency, viral ion, bacterial
infection, spleen disorder, hemodialysis or transplantation, myeloma, lymphoma,
metastatic solid tumors which infiltrate and replace the bone marrow, toxins, bone
marrow failure, Schwachman-Diamond syndrome, cartilage-hair hypoplasia,
dyskeratosis congenita, glycogen storage disease type IB, splenomegaly, or sic
defects in myeloid cells.
Some embodiments provide methods for treating leukopenia comprising the
step of stering a therapeutically effective amount of a compound selected from
Compounds 1-6 to a subject in need thereof. In some embodiments, leukopenia is caused
or associated with one or more diseases or ers selected from aplastic anemia,
mune diseases, herapy, ion, hyperthyroidism, rheumatoid arthritis,
liver disorders, spleen disorders, congenital disorders, viral infections, bacterial
infections and parasitic infections. In some embodiments, leukopenia is caused or
associated with parasitic infection, for example, infection selected from Acanthamoeba
keratitism, amoebiasis, ascariasis, babesiosis, balantidiasis, baylisascariasis, Chagas
disease, clonorchiasis, cochliomyia, cryptosporidiosis, diphyllobothriasis, dracunculiasis,
coccosis, elephantiasis, enterobiasis, fascioliasis, fasciolopsiasis, filariasis,
giardiasis, gnathostomiasis, hymenolepiasis, isosporiasis, Katayama fever, aniasis,
Lyme disease, malaria, metagonimiasis, myiasis, onchocerciasis, pediculosis, scabies,
schistosomiasis, sleeping ss, strongyloidiasis, sis, toxocariasis,
toxoplasmosis, nosis, and trichuriasis. In some embodiments, leukopenia is caused
by or associated with viral ion, for example, infection selected from HCV, HIV,
influenza, Ebola virus, Marburg virus, flavivirus, Venezuelean equine encephalitis,
ation] wilksar
None set by wilksar
[Annotation] wilksar
MigrationNone set by wilksar
[Annotation] wilksar
Unmarked set by r
[Annotation] wilksar
None set by wilksar
[Annotation] wilksar
MigrationNone set by wilksar
ation] wilksar
Unmarked set by wilksar
Chikungunya virus, and West Nile virus. In some embodiments, flavivirus is selected
from the group consisting of Absettarov, Alfuy, Apoi, Aroa, Bagaza, Banzi, Bouboui,
Bussuquara, Cacipacore, Carey , Dakar bat, Dengue l, Dengue 2, Dengue 3,
Dengue 4, Edge Hill, Entebbe bat, Gadgets Gully, Hanzalova, Hypr, Ilheus, Israel turkey
meningoencephalitis, Japanese encephalitis, Jugra, Jutiapa, Kadam, Karshi, Kedougou,
Kokobera, Koutango, Kumlinge, Kunjin, Kyasanur Forest e, Langat, Louping ill,
Meaban, Modoc, Montana myotis leukoencephalitis, Murray valley encephalitis,
Naranjal, Negishi, Ntaya, Omsk hemorrhagic fever, Phnom—Penh bat, Powassan, Rio
Bravo, Rocio, royal farm, Russian spring-summer encephalitis, Saboya, St. Louis
encephalitis, Sal Vieja, San Perlita, Saumarez Reef, Sepik, Sokuluk, Spondweni,
Stratford, Tembusu, Tyuleniy, Uganda S, Usutu, Wesselsbron, west Nile, Yaounde,
yellow fever, and Zika. In some embodiments, leukopenia is caused or ated with
bacterial infection, for example, infection ing from Acidobacteria, Actinobacteria,
Aquificae, Bacteroidetes, Caldiserica, Chlamydiae, Chlorobi, Chloroflexi,
Chrysiogenetes, Cyanobacteria, Deferribacteres, Deinococcus-Thermus, Dictyoglomi,
Elusimicrobia, Fibrobacteres, Firmicutes, Fusobacteria, Gemmatimonadetes,
Lentisphaerae, Nitrospira, Planctomycetes, bacteria, Spirochaetes, istetes,
Tenericutes, utes, Thermodesulfobacteria, Thermomicrobia, Thermotogae, or
Verrucomicrobia.
Some embodiments provide methods for treating a disease or condition
selected from the group consisting of an inflammatory disorder, an allergic disorder, an
autoimmune disease, and a cancer in a subject in need thereof, the method comprising
administering to the human in need thereof a therapeutically effective amount of a
compound ed from Compounds 1-6, or a pharmaceutically acceptable salt, ester or
derivative thereof, n said subject is onally undergoing proton pump inhibitor
therapy, and, n said compound selected from Compounds 1-6 is administered at
an increased daily dosage compared to the daily dosage recommended for a t not
undergoing proton pump inhibitor therapy. In some embodiments, proton pump inhibitor
is selected selected from omeprazole, hydroxyomeprazole, esomeprazole, prazole,
lansoprazole, pantoprazole, rabeprazole, dontoprazole, habeprazole, perprazole,
ransoprazole, pariprazole, prazole, tenatoprazole, S-tenatoprazole-Na, and
deXlansoprazole. For example, a patient oing proton pump therapy is administered
a daily dosage of a compound selected from Compounds 1-6 that is increased by
[Annotation] r
None set by wilksar
[Annotation] wilksar
ionNone set by wilksar
[Annotation] wilksar
Unmarked set by wilksar
[Annotation] wilksar
None set by wilksar
[Annotation] wilksar
ionNone set by wilksar
[Annotation] wilksar
Unmarked set by wilksar
between 25-75% of the ended daily dosage. In one embodiment, the daily dosage
of compound 1 is increased by about 200%, 100%, 75%, 70%, 65%, 60%, 55%, 50%,
45%, 40%, 35%, 30% or 25%. For example, a daily dosage of recommendation of about
800 mg of compound-1 can be increased by about 200%, 100%, 75%, 70%, 65%, 60%,
55%, 50%, 45%, 40%, 35%, 30% or 25% for patient undergoing proton pump inhibitor
therapy. For example, the increased dosage can be about 2400 mg or 1600 mg or 1400
mg or about 1360 mg or about 1320 mg or about 1280 mg or about 1240 mg or about
1200 mg or about 1160 mg or about 1140 mg or about 1100 mg or about 1060 mg or
about 1020 mg or about 980 mg or about 940 mg or about 900 mg. In one embodiment,
the ation provides methods for treating a proliferative disease or disorder in a
subject in need thereof, comprising the step of administering a therapeutically effective
amount of a compound selected from Compounds 1-6, or a pharmaceutically acceptable
salt thereof, to said subject, wherein said subject has one or more al inding
ypes selected from t(8,21)(q22,q22), inv(16)(p13.1q22) and t(16,16)(p13.1,q22),
or wherein said subject has one or more chromosomal abnormalities selected from the
deletion of 5, 5q, 7, 7q, 17p, inv(3)(q21,q26) and t(3,3)(q21,q26), or wherein said
subject has a 11q23 rearrangement of MLL gene.
Cytogenetic data help stratify patients in terms of diagnosis and evaluating
prognosis for survival and risk of transformation to AML (US. Patent Publication No.
20100009364, Hofmann, W.K., et al., Myelodysplastic syndrome. Annual Review of
Medicine. 2005, vol. 56, pp. 1-16). Characteristic chromosomal deletions involve
chromosome 5 [del(5q), -5], chromosome 11 [del(11q)], chromosome 12 [del(12q)],
chromosome 20 [del(20q)], chromosome 7 [del(7q), -7], chromosome 17 [del(17p)], and
chromosome 13 [del(13q)]. Other frequent structural and/or numerical chromosomal
aberrations include trisomy 8, trisomy 21, and ion 26). Rare reciprocal
ocations include t(1, 7)(q10, p10), t(l, 3)(p36, q21), t(3, 3)(q21, q26), t(6, 9)(p23,
q34), and t(5, 12)-fusion between PDGFRB and TEL(ETV-6), (q33, p13), t(5, ,
11.2). Some embodiments provide methods for ng proliferative diseases including
AML and MDS by the administration of a compound selected from Compounds 1-6 or a
pharmaceutically acceptable salt thereof to a t in need thereof.
Some embodiments provide methods for treating a proliferative disease or
disorder in a subject in need thereof, comprising the step of administering a
therapeutically effective amount of a nd selected from Compounds 1-6, or a
ation] wilksar
None set by wilksar
[Annotation] wilksar
MigrationNone set by wilksar
[Annotation] wilksar
Unmarked set by wilksar
[Annotation] wilksar
None set by wilksar
[Annotation] wilksar
MigrationNone set by wilksar
[Annotation] wilksar
Unmarked set by wilksar
pharmaceutically acceptable salt thereof, to said subject, wherein said t has or
expresses a mixed lineage ia (MLL) fusion n, a L fusion protein,
FLT3 internal tandem duplications, a deleted or mutated p53, high or elevated levels of
meningioma 1, and/or high or levels of lactate dehydrogenase.
Homeobox (HOX) proteins are homeo-domain DNA binding transcription
factors that play an important role in regulation of hematopoiesis (Sitwala, Int. J. Clin.
Exp. Pathol. 2008, Mar 30, 1(6):461-74). Myeloid pic Viral Integration Site 1
) is a co-factor of Homeobox A9 (HOXA9) that recruits additional DNA binding
proteins to HOXA9 binding sites in order to maintain the Mixed Lineage Leukemia
(MLL) stem cell transcriptional m (Collins, Curr. Opin. Hematol. 2016, Jul,
23(4):354-61). Over expression of these two proteins in hematopoietic stem cells (HSCs)
results in a rapid and fatal leukemia when transduced HSCs are transplanted in mice
(Thorsteinsdottir, EMBO J. 2001, Feb 1, 20(3):350-61). A subset of acute lymphoid
leukemia (ALL), acute myeloid leukemia (AML), pro-B-acute lymphocytic leukemia
(pro-B ALL), myelodysplastic syndrome (MDS) and T-cell acute lymphoblastic
leukaemia ) patients can be characterized by tumor cells collected from bone
marrow showing high co-expression of HOXA9 and MEISl that may be associated with
increased SYK protein levels. Increased SYK protein expression can be measured by
evaluating pSYK . Some embodiments provide a method for treating patients with
ALL, pro-B ALL, AML, MDS and T-ALL, where HOXA9 and MEISl are
overexpressed, by the administration of a therapeutically effective amount of a SYK
tor selected from Compounds 1-6, or a pharmaceutically acceptable salt, ester or
derivative thereof.
Some embodiments provide methods for treating a proliferative disease or
disorder in a subject in need thereof, comprising the step of stering a
therapeutically ive amount of a compound selected from nds 1-6, or a
pharmaceutically able salt thereof, to said subject, wherein said subject is
administered one or more anti-cancer agents selected from the group consisting of AMG—
330, anti-miR155, AntiJL-l+, CDl l7-MTX aptamer, CD47mAb, CD-98mAb, GO-203c,
hBF4-mAb, LAIR1-mAb, IL-IRAP-mAb, MG006, miR-150, MRX-6313, MSK-777,
SP-2065, SPM-2, FC, TTT-3002, MLL/Menin inhibitor, AML-IL2/CD80,
4GSSDIEM, , AG—l20, AKN-028, ALT 801, Anti-CD44 mAb, ASP-2215, AT-
E AT-406, AT-9283, AZ-1208, BGB-324, BI 836858, EMS-936564, BP01,
[Annotation] wilksar
None set by wilksar
[Annotation] wilksar
MigrationNone set by wilksar
[Annotation] wilksar
Unmarked set by wilksar
[Annotation] wilksar
None set by wilksar
[Annotation] wilksar
MigrationNone set by wilksar
[Annotation] wilksar
ed set by wilksar
Carbozatinib, CB-839, CART-CD123, CART-CD33, CPI-613, CPI-0610, CSL-362,
CWP-232291, n, Dinacilib, DC/AML fusion, Elesclomol, EPZ-5676,
9552, IGN 523, INNO-305, Iomab-B, KX-2391, LeY, LOR-253, MK-8242,
MGD006, OXi-4503, PF-449913, Plerixafor, FRI-724, anib, Rigosertib, RO-
5503781, PF-04449913, SG—2000, SL-401, SGN—CD33a, TCN—P, Tiecycline,
Triciribine, Vismodegib, Zosuquidar, Actimab-A, AEG 35156, Belinostat, B1811283,
-A, Birinapant, BL-8040, CC-486, CNDO-109, Crenolanib, Deformolus, DFP-
10917, Flavopiridol, GVAX, KB-004, KPT-330, Lestartinib, Lirilumab, LO-02040,
LY209314, MK8776, OmacetaXine, Pacritinib, Panobinostat, , Pdilizumab, PR-
104, Pracinostat, PLX-3397, R-115777, Ribovarin, Selumetinib, SGI-110, Sorafenib,
Tresosulfan, Temodar, Tosedostat, Vorinostat, WT-1, ArseniX trioxide, Clofarabine,
Decitabine, Laromustine, Tipfamib and Mylotarg.
Some embodiments provide s of treatment for anemia,
thrombocytopenia, leukopenia or neutropenia wherein said patient is not undergoing
chemotherapy. For example, the subject is treated with a compound selected from
Compounds 1-6 while the subject is not undergoing chemotherapy with agents such as
DNA damaging agents, antibiotic agents, antimitotic agents, steroids or glucocorticoids.
DNA ting agents can be selected from, for example, mycin, amsacrine,
busulfan, carboplatin, chlorambucil, tin, cyclophosphamide, Cytoxan,
dactinomycin, daunorubicin, doxorubicin, epirubicin, iphosphamide, melphalan,
merchlorethamine, mitomycin, mitoxantrone, nitrosourea, procarbazine, Taxol, Taxotere,
teniposide, etoposide and triethylenethiophosphoramide. The antibiotic chemotherapy
agents can be selected from dactinomycin (actinomycin D), daunorubicin, doxorubicin
(adriamycin), idarubicin, cyclines, mitoxantrone, bleomycins, plicamycin
(mithramycin) and mitomycin. The antimitotic agents can be selected from vinca
alkaloids, a taxane, nocodazole, epothilones, navelbine and epidipodophyllotoxin. Vinca
alkaloids can be selected from vinblastine and vincristine, or derivatives thereof.
s can be selected from paclitaxel and xel, or derivatives thereof.
ceutical itions andModes ofAdministration
Compounds ed herein are usually stered in the form of
pharmaceutical compositions. Thus, provided herein are also pharmaceutical
compositions that contain one or more of the compounds of any of the formulae
Elosed herein or a pharmaceutically acceptable salt, isomer, g, or solvate
[Annotation] wilksar
None set by wilksar
[Annotation] wilksar
MigrationNone set by wilksar
[Annotation] wilksar
Unmarked set by wilksar
ation] wilksar
None set by wilksar
ation] wilksar
MigrationNone set by wilksar
[Annotation] r
Unmarked set by r
thereof, and one or more pharmaceutically acceptable vehicles ed from carriers,
adjuvants and excipients. Suitable pharmaceutically acceptable vehicles may e, for
example, inert solid diluents and fillers, diluents, including sterile aqueous solution and
various organic solvents, permeation enhancers, solubilizers and adjuvants. Such
compositions are ed in a manner well known in the pharmaceutical art. See, 6. g. ,
Remington’s Pharmaceutical es, Mace Publishing Co., Philadelphia, Pa. 17th Ed.
(1985), and Modern Pharmaceutics, Marcel Dekker, Inc. 3rd Ed. (GS. Banker & C.T.
Rhodes, Eds).
The pharmaceutical compositions may be administered in either single or
multiple doses. The pharmaceutical composition may be administered by various
s including, for example, rectal, buccal, intranasal and transdermal routes. In
certain ments, the pharmaceutical composition may be administered by intra-
arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly,
subcutaneously, orally, topically, or as an inhalant. In some embodiments, the
pharmaceutical composition is administered orally.
One mode for administration is eral, for example, by inj ection. The
forms in which the ceutical compositions described herein may be orated
for administration by injection include, for example, aqueous or oil suspensions, or
emulsions, with sesame oil, corn oil, cottonseed oil, or peanut oil, as well as elixirs,
mannitol, se, or a sterile aqueous solution, and similar pharmaceutical vehicles.
Oral administration may be another route for administration of the
compounds described herein. Administration may be via, for example, capsule or enteric
coated tablets. In making the pharmaceutical compositions that include at least one
compound of any of the formulae described herein or a pharmaceutically acceptable salt,
g, or solvate thereof, the active ingredient is usually diluted by an ent and/or
enclosed within such a carrier that can be in the form of a capsule, sachet, paper or other
container. When the excipient serves as a diluent, it can be in the form of a solid, semi-
solid, or liquid al, which acts as a vehicle, carrier or medium for the active
ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges,
sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or
in a liquid medium), ointments containing, for e, up to 10% by weight of the
active compound, soft and hard gelatin capsules, sterile inj ectable solutions, and sterile
[Annotation] wilksar
None set by wilksar
[Annotation] wilksar
MigrationNone set by wilksar
[Annotation] wilksar
Unmarked set by wilksar
[Annotation] r
None set by wilksar
[Annotation] wilksar
MigrationNone set by wilksar
[Annotation] wilksar
Unmarked set by wilksar
packaged s. In certain embodiments, the pharmaceutical ition is in the
form of tablets.
As used herein, “pharmaceutically acceptable carrier” or aceutically
able ent” includes any and all solvents, dispersion media, coatings,
antibacterial and ngal agents, ic and absorption delaying agents and the like.
The use of such media and agents for pharmaceutically active substances is well known
in the art. Except r as any conventional media or agent is incompatible with the
active ingredient, its use in the therapeutic compositions is contemplated.
Supplementary active ingredients can also be incorporated into the compositions.
Some examples of suitable excipients include lactose, dextrose, sucrose,
sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth,
gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose,
sterile water, syrup, and methyl cellulose. The formulations can onally include
ating agents such as talc, magnesium stearate, and mineral oil, wetting agents,
emulsifying and suspending agents, preserving agents such as methyl and
propylhydroxy-benzoates, sweetening agents, and flavoring agents.
The compositions that include at least one compound of any of the formulae
described herein or a. pharmaceutical ly acceptable salt, isomer, prodrug, or solvate
thereof, can be formulated so as to provide quick, sustained or delayed release of the
active ingredient after administration to the t by employing procedures known in
the art. Controlled e drug delivery systems for oral stration include osmotic
pump systems and dissolution systems containing polymer-coated oirs or drug-
polymer matrix formulations. Examples of controlled release systems are given in US.
Patent Nos. 3,845,770, 4,326,525, 4,902,514 and 5,616,345. Another formulation for use
in the methods of the present application employs transdermal delivery s
(“patches”). Such transdermal patches may be used to provide continuous or
discontinuous infusion of the compounds described herein in controlled amounts. The
construction and use of transdermal patches for the delivery of pharmaceutical agents is
well known in the art. See, e.g., US. Patent Nos. 5,023,252, 4,992,445 and 5,001,139.
Such patches may be ucted for continuous, pulsatile, or on demand delivery of
pharmaceutical agents.
[Annotation] wilksar
None set by wilksar
ation] wilksar
ionNone set by wilksar
[Annotation] wilksar
Unmarked set by wilksar
[Annotation] r
None set by wilksar
[Annotation] wilksar
MigrationNone set by wilksar
[Annotation] wilksar
Unmarked set by wilksar
For preparing solid compositions such as tablets, the principal active
ingredient may be mixed with a pharmaceutical excipient to form a solid preformulation
composition containing a homogeneous mixture of a compound of any of the above
formulae or a pharmaceutically acceptable salt, prodrug, or e thereof. When
referring to these preformulation compositions as neous, the active ingredient
may be dispersed evenly throughout the ition so that the composition may be
readily subdivided into equally effective unit dosage forms such as tablets, pills and
capsules.
The tablets or pills of the compounds described herein may be coated or
otherwise compounded to provide a dosage form affording the advantage of prolonged
, or to protect from the acid conditions of the stomach. For example, the tablet or
pill can include an inner dosage and an outer dosage component, the latter being in the
form of an envelope over the former. The two components can be separated by an enteric
layer that serves to resist disintegration in the stomach and permit the inner component to
pass intact into the duodenum or to be delayed in release. A variety of materials can be
used for such enteric layers or coatings, such materials including a number of polymeric
acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and
cellulose acetate.
Compositions for inhalation or insufflation may e ons and
suspensions in ceutically acceptable, aqueous or organic solvents, or mixtures
thereof, and powders. The liquid or solid compositions may contain suitable
pharmaceutically acceptable excipients as described supra. In some embodiments, the
compositions are administered by the oral or nasal atory route for local or systemic
. In other embodiments, compositions in pharmaceutically acceptable solvents may
be nebulized by use of inert gases. Nebulized ons may be inhaled directly from the
nebulizing device or the nebulizing device may be attached to a facemask tent, or
ittent positive pressure breathing machine. Solution, suspension, or powder
compositions may be administered, ably orally or nasally, from devices that deliver
the formulation in an appropriate manner.
Dosing
The specific dose level of compounds described herein for any particular
subject will depend upon a variety of factors including the ty of the specific
[Annotation] wilksar
None set by wilksar
[Annotation] r
MigrationNone set by r
[Annotation] wilksar
Unmarked set by wilksar
[Annotation] wilksar
None set by wilksar
[Annotation] wilksar
MigrationNone set by r
[Annotation] wilksar
Unmarked set by wilksar
compound employed, the age, body weight, l health, sex, diet, time of
administration, route of administration, and rate of excretion, drug combination and the
severity of the particular disease in the subject undergoing y. For example, a
dosage may be expressed as a number of milligrams of a compound of the formula per
kilogram of the subj ect’s body weight (mg/kg). Dosages of between about 0.01 and 200
mg/kg may be appropriate. In some embodiments, about 0.01 and 150 mg/kg may be
riate. In other embodiments a dosage of between 0.05 and 100 mg/kg may be
appropriate. Normalizing according to the subj ect’s body weight is particularly useful
when adjusting dosages between subjects of widely disparate size, such as occurs when
using the drug in both children and adult humans or when converting an effective dosage
in a non-human subject such as dog to a dosage suitable for a human subject.
The daily dosage may also be described as a total amount of a compound of
the formulae administered per dose or per day. Daily dosage of a compound may be
n about 1 mg and 2,000 mg, between about 1,000 to 2,000 , between about
1 to 1,000 mg/day, between about 1 to 500 mg/day, between about 100 to 150 mg/day,
n about 1 to 100 mg/day, between about 1 to 50 mg/day, between about 50 to 100
mg/day, between about 100 to 125 mg/day, n about 100 to 150 mg/day, between
about 100 to 175 mg/day, between about 100 to 200 mg/day, between about 100 to 225
mg/day, between about 100 to 250 mg/day, between about 100 to 350 mg/day, between
about 100 to 400 mg/day, n about 100 to 450 mg/day, or between about 100 to
500 mg/day.
When stered orally, the total daily dosage for a human subject may be
between 1 mg and 1,000 mg/day, between about 1 to 100 mg/day, between about 1 to 50
mg/day, between about 50 to 100 mg/day, n 50 to 300 mg/day, between 50 to 200
mg/day, between 75 to 200 mg/day, between 75 to 150 mg/day, between 100 to 200
mg/day, between about 200 to 300 mg/day, between about 300 to 400 mg/day, between
about 400 to 500 mg/day, between about 100 to 150 mg/day, between about 150 to 200
mg/day, between about 200 to 250 mg/day, between about 75 to 150 mg/day, or between
about 150 to 300 .
The compounds of the present application or the compositions thereof may be
administered once, twice, three, or four times daily, using any suitable mode described
above.
[Annotation] wilksar
None set by wilksar
[Annotation] wilksar
MigrationNone set by wilksar
[Annotation] wilksar
Unmarked set by r
[Annotation] wilksar
None set by wilksar
[Annotation] wilksar
MigrationNone set by wilksar
ation] wilksar
Unmarked set by wilksar
Example
Methods: In this phase 1b/2 study (NCT02343939), patients age 18 to 70
years with previously untreated AML, preserved organ on, and ECOG S 2 were
eligible to receive dose escalated letinib (ENTO or Compound-1) for 14 days as
monotherapy (days -14 to 0) followed by combination with daunorubicin 60 mg/m2/d,
cycle 1 day 1 to 3, and cytarabine 100 mg/m2/d, cycle 1 day 1 to 7. All patients received
entospletinib (ENTO or Compound-1) monotherapy for up to 14 days prior to starting
induction. Chemotherapy could be initiated after 5 days of monotherapy (and
entospletinib continued for 4+ weeks) in patients with leukemia-related cations
necessitating chemotherapy. Patients enrolled to dose level (DL) 0 and DL 1 received
entospletinib 200 mg po BID and 400 mg po BID, respectively. Patients with residual
disease two weeks after chemotherapy received a second induction cycle identical to the
first. Entospletinib was continued without interruption until remission was assessed at
count recovery.
Results: Twelve patients enrolled with a median age of 54 (range, 18—69)
years. Patients were in the following an LeukemiaNet genetic risk :
favorable (n=1), intermediate I (n=3), intermediate II (n=2), and adverse (n=4),
respectively. Three patients were not evaluable for dose limiting toxicity (DLT)
assessment and were replaced (due to detection of CNS disease requiring non-study
therapy (n=1), and withdrawal of consent unrelated to drug ty (n=2)). Single-agent
entospletinib during the window period was well tolerated, ties after combination
with intensive herapy were common and typical. Among three patients treated at
200 mg BID, no DLT was observed. Of three patients treated at 400 mg BID, a patient
with documented fungal pneumonia ped grade 3 pneumonitis that was possibly
related to entospletinib. Although this did not meet DLT criteria, DL 1 was expanded
with 3 additional ts, none of whom experienced DLT. Overall, the most common
non hematologic adverse events (inclusive of intensive chemotherapy periods) were
febrile neutropenia, nausea, and diarrhea. Based on this clinical experience and compiled
cokinetic data demonstrating lack of benefit to r dose escalation, 400 mg
BID was selected as the recommended phase 2 dose. Responses were seen at both levels.
Among the 3 patients treated at 200 mg BID, two required a second ion but each
ed a complete remission (CR) (3/3, 100%). Of the 6 patients treated at 400 mg
BID, none required a second induction and the CR rate was also 100%. Remarkably, an
[Annotation] wilksar
None set by wilksar
ation] wilksar
MigrationNone set by wilksar
[Annotation] wilksar
ed set by wilksar
[Annotation] wilksar
None set by wilksar
[Annotation] wilksar
MigrationNone set by r
[Annotation] wilksar
Unmarked set by wilksar
18 year old male with 11q23-rearranged AML achieved morphologic and cytogenetic
CR after only the 14 day entospletinib monotherapy window (prior to chemotherapy).
Another patient with 11q23-rearranged AML had significant platelet response during the
window period (this patient refused disease evaluation by marrow aspiration prior to
chemotherapy).
A neutrophil recovery plot for all enrolled subjects in the above study is
provided in Figure 1. During the letinib monotherapy lead-in period, te
neutrophil counts (ANC) remained y stable. All three of the ble subjects at
the entospletinib 400 mg dose level who were under the severe neutropenia cutoff of
200/uL ANC at baseline recovered to above 200/uL during treatment. Severe
neutropenia in these subjects was short lived, with a median (Q1, Q3) time to recovery of
8 (8, 14) days, individual values were 8, 8, and 14 days. The only evaluable subject with
severe neutropenia at baseline at the entospletinib 200 mg dose level also recovered
during treatment (recovery time of 66 days). Among the five subjects (treated at both
entospletinib dose levels) who did not have severe neutropenia at baseline and had at
least one post-baseline ANC assessment, none experienced severe neutropenia at any
time during induction treatment, however, two of the five ts, both treated at the
entospletinib 400 mg dose level, did ence severe neutropenia during the
entospletinib monotherapy lead-in period, which recovered to above 200/uL by the end
of the first induction cycle in both subjects (Figure 1).
A plot of et counts through induction treatment for all ed subjects
in the above study is provided in Figure 2. During the two week entospletinib
monotherapy window, platelet count remained stable, or in some cases, improved from
baseline. One subject received platelet transfusions at the entospletinib 200 mg dose
level and no transfusions were required at the entospletinib 400 mg dose level. During
induction ent, the mean number of transfusions ed per subject was 4.1 during
Cycle 1 and 5.5 during Cycle 2. Across the monotherapy lead-in and induction treatment
cycles, the mean number of platelet transfusions ed per subject was 8.7 at the
ENTO 200 mg dose level, 4.1 at the entospletinib 400 mg dose level, and 5.5 overall
(Figure 3).
Throughout this specification, various patents, patent applications and other
types of publications (e.g., journal articles) are referenced. The disclosure of all patents,
[Annotation] wilksar
None set by wilksar
ation] wilksar
MigrationNone set by r
[Annotation] wilksar
Unmarked set by wilksar
[Annotation] wilksar
None set by wilksar
[Annotation] wilksar
MigrationNone set by wilksar
[Annotation] wilksar
Unmarked set by wilksar
patent applications, and publications cited herein are hereby incorporated by reference in
their entirety for all purposes.
Claims (6)
1. Use of a therapeutically effective amount of a compound selected from , , Compound-1 Compound-2 , , and Compound-3 Compound-4 Compound-5 or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating or reducing aplastic anemia in a subject.
2. Use according to claim 1 n the compound is or a pharmaceutically acceptable salt thereof.
3. Use according to claim 1 wherein the compound is or a ceutically acceptable salt thereof.
4. Use according to claim 1 wherein the compound is or a pharmaceutically acceptable salt thereof.
5. Use according to claim 1 wherein the compound is or a pharmaceutically acceptable salt thereof.
6. Use according to claim 1 wherein the compound is or a pharmaceutically able salt thereof.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662394573P | 2016-09-14 | 2016-09-14 | |
US62/394,573 | 2016-09-14 | ||
US201662416047P | 2016-11-01 | 2016-11-01 | |
US62/416,047 | 2016-11-01 | ||
US201662429209P | 2016-12-02 | 2016-12-02 | |
US62/429,209 | 2016-12-02 | ||
PCT/US2017/051649 WO2018053190A1 (en) | 2016-09-14 | 2017-09-14 | Syk inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ750789A NZ750789A (en) | 2021-02-26 |
NZ750789B2 true NZ750789B2 (en) | 2021-05-27 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10111882B2 (en) | SYK inhibitors | |
List et al. | Opportunities for Trisenox®(arsenic trioxide) in the treatment of myelodysplastic syndromes | |
EP2127652B1 (en) | Method for treating cancer using anticancer agent in combination | |
JP6757959B2 (en) | Anti-cancer agent | |
TW200425898A (en) | Method and compositions for treating flaviviruses and pestiviruses | |
KR20190015353A (en) | Antifungal phosphoramidate nucleoside derivatives | |
CN106102745A (en) | Treat and prevent the method for graft versus host disease(GVH disease) | |
TW201107327A (en) | Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agent | |
Thieblemont et al. | Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma | |
CA3187767A1 (en) | Alk2 inhibitors for the treatment of anemia | |
WO2018015526A1 (en) | Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof | |
Zhang et al. | Etoposide in combination with low-dose CAG (cytarabine, aclarubicin, G-CSF) for the treatment of relapsed or refractory acute myeloid leukemia: a multicenter, randomized control trial in southwest China | |
ES2426098T3 (en) | Pharmaceutical compositions and their use in cancer treatment | |
KR102505218B1 (en) | Combinations of BCL-2 inhibitors and MCl-1 inhibitors, uses and pharmaceutical compositions thereof | |
Koh et al. | Combinatorial immunotherapy with gemcitabine and ex vivo-expanded NK cells induces anti-tumor effects in pancreatic cancer | |
TW202002989A (en) | Antitumor agent, antitumor effect potentiator and antitumor kit | |
NZ750789B2 (en) | Imidazopyrazine syk inhibitors for the treatment of cancers and other hyperproliferative disorders | |
Boyé et al. | Dose escalation study to evaluate safety, tolerability and efficacy of intravenous etoposide phosphate administration in 27 dogs with multicentric lymphoma | |
KR20150136073A (en) | Antitumor agent including irinotecan hydrochloride hydrate | |
JP2021504385A (en) | How to Inhibit Tumor Metastasis | |
CN114225023B (en) | Application of anti-CSF-1R antibody and anti-PD-L1 antibody in combination | |
US20240139196A1 (en) | Combination treatments in difficult to treat patients with advanced and/or metastatic trop-2 overexpressing cancers | |
WO2021095599A1 (en) | Pd-1 signal inhibitor combination therapy | |
Zhang et al. | ATF4 drives the resistance of T-ALL against FGFR1 inhibitors through amino acid metabolic reprogramming | |
Wang et al. | Recent progress in chimeric antigen receptor therapy for acute myeloid leukemia |